Mounjaro and Zepbound are Glucose Dependent Insulinotropic Polypeptide (GIP) AND a Glucagon-Like Peptide (GLP-1) Receptor agonist. They are both brand names for the drug known as Tirzepatide. Instead of working on only one naturally occurring hormone in the body (GLP-1) as Wegovy, Saxenda, and Ozempic do, they work on two (GLP-1 and GIP) hormones in the body to help promote weight loss and improve blood sugar. In summary Mounjaro and Zepbound not only promote the release of insulin like Wegovy, Saxenda, and Ozempic but also reduces glucagon levels to help regulate blood sugar before and after meals, slows gastric emptying, and reduces appetite.
 

• Insulin is a natural occurring hormone that reduces blood sugar levels.
• Glucagon is a natural occurring hormone that increases blood sugar.

The main differences and similarities between the two drugs include:

• Hormones influenced: Same
• Dosing strengths: Same
• Generic name: Tirzepatide (both)
• FDA approval:
  • Mounjaro is FDA approved for type 2 diabetes and used off label for weight loss.
  • Zepbound is FDA approved for the treatment of overweight and obesity diagnosis.
• Average weight loss:
  • Some adults taking Mounjaro achieved up to 22% weight loss.
  • 1 in 3 adults taking Zepbound achieved 25% weight loss at the highest dose.

Both drugs are to be used in conjunction with diet and exercise to achieve desired results. Please contact our office to find out how we can help you to get started on your weight loss journey.